Pantherna Therapeutics GmbH

Pantherna Therapeutics is a biotechnology startup based in Germany that is focused on developing novel mRNA-based therapeutics. The company, founded in 2017, aims to address unmet medical needs with its innovative PTX platform technologies. These include robust mRNA expression constructs (PTXmRNA) and lipid nanoparticle (LNP) delivery vehicles (PTX_LNP) for localized expression of therapeutic proteins. The company's first development candidate, PAN004, utilizes a defined mRNA-LNP formulation for selective mRNA delivery and expression of a Tie2-agonist in the vascular endothelium of the lung. Pantherna is also working on expanding its pipeline with various novel mRNA-LNP candidates that enable the therapeutic use of mRNA in different tissues such as skeletal muscle or immune cells. In July 2019, Pantherna Therapeutics secured a €3.50M Seed Round investment from EIF, Detlev Riesner, and HTGF (High-Tech Gruenderfonds). This investment highlights the confidence of these investors in Pantherna's innovative approach to mRNA therapeutics and its potential to make a meaningful impact in addressing unmet medical needs.